- Home
- PCRX vs EIM Comparison
PCRX vs EIM Comparison
Compare PCRX & EIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- EIM
- Stock Information
- Founded
- PCRX 2006
- EIM 2002
- Country
- PCRX United States
- EIM United States
- Employees
- PCRX N/A
- EIM N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- EIM Finance/Investors Services
- Sector
- PCRX Health Care
- EIM Finance
- Exchange
- PCRX Nasdaq
- EIM Nasdaq
- Market Cap
- PCRX 1.2B
- EIM 522.9M
- IPO Year
- PCRX 2011
- EIM N/A
- Fundamental
- Price
- PCRX $22.90
- EIM $9.53
- Analyst Decision
- PCRX Buy
- EIM
- Analyst Count
- PCRX 8
- EIM 0
- Target Price
- PCRX $28.38
- EIM N/A
- AVG Volume (30 Days)
- PCRX 525.8K
- EIM 215.2K
- Earning Date
- PCRX 07-29-2025
- EIM 01-01-0001
- Dividend Yield
- PCRX N/A
- EIM 4.32%
- EPS Growth
- PCRX N/A
- EIM N/A
- EPS
- PCRX N/A
- EIM N/A
- Revenue
- PCRX $702,772,000.00
- EIM N/A
- Revenue This Year
- PCRX $7.92
- EIM N/A
- Revenue Next Year
- PCRX $11.02
- EIM N/A
- P/E Ratio
- PCRX N/A
- EIM N/A
- Revenue Growth
- PCRX 3.08
- EIM N/A
- 52 Week Low
- PCRX $11.16
- EIM $8.61
- 52 Week High
- PCRX $27.64
- EIM $10.51
- Technical
- Relative Strength Index (RSI)
- PCRX 35.82
- EIM 40.91
- Support Level
- PCRX $22.82
- EIM $9.56
- Resistance Level
- PCRX $23.83
- EIM $9.63
- Average True Range (ATR)
- PCRX 0.74
- EIM 0.05
- MACD
- PCRX -0.02
- EIM -0.00
- Stochastic Oscillator
- PCRX 6.22
- EIM 25.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About EIM Eaton Vance Municipal Bond
Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.